0001047469-03-038794 Sample Contracts

Date: September 2003 ELAN CORPORATION, PLC. AND ACORDA THERAPEUTICS, INC. AMENDED AND RESTATED LICENSE AGREEMENT
License Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree that each of the MS Agreement and the SCI Agreement, and all of the terms, conditions and provisions of the MS Agreement and the SCI Agreement, are hereby superceded and replaced and restated in their entirety by this Agreement and the Supply Agreement and the terms, conditions and provisions hereof and thereof, as of the Amendment Date, as follows and as set forth in the Supply Agreement:

Sample 1Sample 2Sample 3See All (6)
AutoNDA by SimpleDocs
Mr. Mark Pinney
Acorda Therapeutics Inc • November 28th, 2003 • Biological products, (no disgnostic substances) • New York

We are delighted to present this letter agreement, setting out the terms of your continued employment with Acorda Therapeutics, Inc. (the “Company”) as Chief Financial Officer. If these terms are acceptable, please sign and date the copy of this letter provided herewith and return it to me at your first convenience. If you accept the terms offered herein, this Agreement shall be deemed to be effective as of September 1, 2003 (the “Effective Date”).

Sample 1Sample 2Sample 3See All (5)
Date: September 2003 ELAN CORPORATION, PLC. AND ACORDA THERAPEUTICS, INC. SUPPLY AGREEMENT
Supply Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3See All (5)
LICENSE AGREEMENT by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER and ACORDA THERAPEUTICS, INC.
License Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

THIS LICENSE AGREEMENT effective as of September 26, 2003 (“Effective Date”), by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER, an Illinois not-for-profit corporation and having its principal office at 1725 W. Harrison St. Chicago, Ill. 60612 (“RUSH”) and ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 15 Skyline Drive, Hawthorne, New York 10532 (“ACORDA”).

Sample 1Sample 2Sample 3See All (5)
LICENSE AGREEMENT
License Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

Report royalty payment information to the Cornell Research Foundation, Inc (CRF) using the report format or facsimile attached to these instructions. This minimal information must be provided in order to correctly record royalty related events required by your license agreement with CRF.

Sample 1Sample 2Sample 3See All (4)
SECURITIES AMENDMENT AGREEMENT AMONG ELAN CORPORATION, PLC, ELAN INTERNATIONAL SERVICES, LTD. and ACORDA THERAPEUTICS, Inc.
Securities Amendment Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

IN CONSIDERATION OF THE MUTUAL COVENANTS CONTAINED HEREIN, AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND ADEQUACY OF WHICH ARE HEREBY ACKNOWLEDGED, IT IS HEREBY AGREED AS FOLLOWS:

Sample 1Sample 2Sample 3
TERMINATION AND ASSIGNMENT AGREEMENT ELAN CORPORATION, PLC ELAN INTERNATIONAL SERVICES, LTD. ACORDA THERAPEUTICS, Inc. MS RESEARCH AND DEVELOPMENT CORPORATION
Termination and Assignment Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

IN CONSIDERATION OF THE MUTUAL COVENANTS CONTAINED HEREIN, AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND ADEQUACY OF WHICH ARE HEREBY ACKNOWLEDGED, IT IS HEREBY AGREED AS FOLLOWS:

Sample 1Sample 2Sample 3
AMENDED AND RESTATED LICENSE AGREEMENT by and between CANADIAN SPINAL RESEARCH ORGANIZATION and ACORDA THERAPEUTICS, INC.
License Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York
Sample 1Sample 2Sample 3
LICENSE AGREEMENT BETWEEN ACORDA THERAPEUTICS, INC. AND THE MAYO FOUNDATION FOR EDUCATION AND RESEARCH Dated: September 8, 2000
License Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • Minnesota

THIS LICENSE AGREEMENT (this “Agreement”) is entered into as of September 8, 2000 (the “Effective Date”), by and between Acorda Therapeutics, Inc., a Delaware corporation, having offices at 15 Skyline Drive, Hawthorne, New York 10532, (“ACORDA”) and The Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation located at 200 First Street SW, Rochester, Minnesota 55905 (“MAYO”).

Sample 1Sample 2Sample 3
LABORATORY SERVICES AGREEMENT
Laboratory Services Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

This Laboratory Services Agreement (“Agreement”) effective as of April 1, 2003 (the “Effective Date”) is between Acorda Therapeutics, Inc. with an address at 15 Skyline Drive, Hawthorne, New York 10532, USA (“Acorda”) and Cardinal Health PTS, Inc. with an address of 160 Magellan Labs Ct., Morrisville, North Carolina, USA (“Cardinal Health”).

Sample 1Sample 2
COLLABORATION AGREEMENT by and between TEVA PHARMACEUTICAL INDUSTRIES LTD. and ACORDA THERAPEUTICS, INC.
Collaboration Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

This letter shall confirm our agreement regarding a possible collaboration agreement to develop, co-promote and commercialize in the United States (including its possessions and territories), Canada and Mexico (collectively, the “Territory”) all finished pharmaceutical products that contain Acorda’s chemical compound referred to as fampridine (the “Fampridine Agreement”).

Sample 1Sample 2
AERES BIOMEDICAL LIMITED ACORDA THERAPEUTICS
Research Collaboration and Commercialisation Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • England

Certain portions of this Exhibit have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission.

Sample 1Sample 2
RXPEDITE ACORDA MARKETING SERVICES AGREEMENT
Marketing Services Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

This Marketing Services Agreement (the “Agreement”) is made effective as of September 19, 2003 (the “Effective Date”), by and between Creative Healthcare Solutions, LLC, an Ohio limited liability corporation with offices at 500 Olde Worthington Road, Westerville, Ohio 43082 (“CHS”) and Acorda Therapeutics, Inc., a Delaware corporation having its principal place of business at 15 Skyline Drive, Hawthorne, New York 10532 (“Client”).

Sample 1Sample 2
AGREEMENT between LONZA BIOLOGICS PLC and ACORDA THERAPEUTICS
Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • England and Wales
Sample 1Sample 2
RXPEDITE ACORDA MARKETING SERVICES AGREEMENT
Acorda Marketing Services Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

This Marketing Services Agreement (the “Agreement”) is made effective as of September 19, 2003 (the “Effective Date”), by and between Cardinal Health PTS, Inc., a corporation with offices at 7000 Cardinal Place, Dublin, Ohio 43017 (“Cardinal Health”) and Acorda Therapeutics, Inc., a Delaware corporation having its principal place of business at 15 Skyline Drive, Hawthorne, New York 10532 (“Client”).

Sample 1Sample 2
RUSH PAYMENTS AGREEMENT
Rush Payments Agreement • November 28th, 2003 • Acorda Therapeutics Inc • Biological products, (no disgnostic substances) • New York

REFERENCE IS MADE to (i) the License Agreement effective as of September , 2003, by and between RUSH-PRESBYTERIAN-ST. LUKE’S MEDICAL CENTER, a [ ] and having its principal office at [1650 W. Harrison St. Chicago, Ill. 60612 (“Rush”), and ACORDA THERAPEUTICS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 15 Skyline Drive, Hawthorne, New York 10532 (“Acorda”), including the Side Agreement attached thereto as Exhibit 1.31 by and among Rush, Acorda and Elan (as defined below) (the “Side Agreement”), a copy of which is attached as Exhibit A hereto (the “Rush/Acorda License”); and (ii) the Amended and Restated License Agreement effective as of September , 2003 by and between Acorda and ELAN CORPORATION, PLC., a public limited company incorporated under the laws of Ireland and having its registered office at Lincoln House, Lincoln Place, Dublin 2, Ireland (“Elan”) (the “Elan/Acorda License”). The Rush/Acorda License and t

Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.